<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01078714</url>
  </required_header>
  <id_info>
    <org_study_id>RB09-017</org_study_id>
    <nct_id>NCT01078714</nct_id>
  </id_info>
  <brief_title>Efficiency of Bumetanide in Autistic Children</brief_title>
  <acronym>BUMEA</acronym>
  <official_title>Study of the Efficiency of a Treatment by Bumetanide in a Population of Autistic Children</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Brest</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Brest</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine if a treatment by bumetanide presents an efficiency
      at the level of the neuronal maturation in the autism
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2010</start_date>
  <completion_date type="Actual">June 2011</completion_date>
  <primary_completion_date type="Actual">June 2011</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Child Autism Rating Scale score</measure>
    <time_frame>day 0 to day 90</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical global impressions score</measure>
    <time_frame>day 0 to day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Repetitive end restricted behavior score</measure>
    <time_frame>day 0 to day 90</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>GRAM score</measure>
    <time_frame>day 0 to day 90</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Autistics Children</condition>
  <arm_group>
    <arm_group_label>Bumetanide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>bumetanide</intervention_name>
    <description>Administration by oral route in 2 times (in the morning and evening) of 0.5 mg by taking (= 1 mg by 24 hours)</description>
    <arm_group_label>Bumetanide</arm_group_label>
    <arm_group_label>Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Children from 3 to 10 years old, answering the diagnosis of typical autism according
             to the diagnostic criteria of autism of the classification of the WHO ( CIM-10) and
             the parents of which gave a free, enlightened and written consent.

        Exclusion Criteria:

          -  Patients epileptic autistics treated by anticomitiaux or having hurts of the central
             nervous system

          -  Patients autistics receiving a psychotropic treatment

          -  Patients presenting disorders electrolytes

          -  Patients presenting a hypersensibility known about sulpha drugs

          -  Presenting patients against indications relative to the treatment by bumetanide

          -  Patients already treated by diuretics

          -  Patients presenting a hepatic or renal incapacity

          -  Patients presenting an elongation of the QT to the electrocardiogram.

          -  Patients autistics of CARS sore is lower than 30.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>3 Years</minimum_age>
    <maximum_age>10 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric LEMONNIER, Dr</last_name>
    <role>Principal Investigator</role>
    <affiliation>CHRU de Brest</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Lemonnier</name>
      <address>
        <city>Brest</city>
        <zip>29609</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chevreuil</name>
      <address>
        <city>Rennes</city>
        <zip>35703</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DUPIN</name>
      <address>
        <city>Vannes</city>
        <zip>56000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>December 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 1, 2010</study_first_submitted>
  <study_first_submitted_qc>March 1, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 2, 2010</study_first_posted>
  <last_update_submitted>December 20, 2011</last_update_submitted>
  <last_update_submitted_qc>December 20, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 21, 2011</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Autism</keyword>
  <keyword>Bumetanide</keyword>
  <keyword>GABA</keyword>
  <keyword>NKCC1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Autistic Disorder</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bumetanide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

